Tiziana life sciences to participate in a fireside chat at the b. riley securities 2022 oncology conference

New york, jan. 26, 2022 (globe newswire) -- tiziana life sciences ltd (nasdaq: tlsa) ("tiziana" or the "company"), a clinical-stage biopharmaceutical company developing breakthrough therapies for kras+ non-small cell lung cancer (nsclc) and transformational drug delivery technologies to enable alternative routes of immunotherapy, today announced its chief executive officer and chief scientific officer, kunwar shailubhai, ph.d., will participate in a virtual fireside chat at the b.riley securities 2022 oncology conference on thursday, 27 january 2022 at 4:00 p.m. edt (u.s. and canada) to provide company updates.
TLSA Ratings Summary
TLSA Quant Ranking